Nandani Creation DuPont analysis

·UnclassifiedChart ›
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.69×0.68×0.72×0.99×0.77×
0.40×0.44×0.73×0.23×0.07×
5.9%5.9%10.2%5.2%4.2%
1.02×1.02×0.86×0.76×1.16×
1.94×1.94×1.77×—1.66×
3.2%3.5%8.1%—0.4%
3.4%3.4%9.0%1.9%0.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JAIPURKURT₹28.81

Nandani Creation Limited

· Unclassified
₹ CrorePeersAGROPHOSAHLADAGANGAFORGEKSHITIJPOLRKECMASKINVESTDANGEETOUCHWOODMcap ₹55 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.770.990.720.680.69
Interest Burden (Pretax/EBIT) ×0.070.230.730.440.40
EBIT Margin %4.195.2110.195.935.88
Asset Turnover ×1.160.760.861.021.02
Financial Leverage (Assets/Equity) ×1.66—1.771.941.94
ROE (5-step product, year-end total equity) %0.43—8.133.493.22
ROE (owners' profit / average owners' equity) %0.381.869.043.353.35
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.